Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.

about

Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.

Item

http://www.wikidata.org/entity/Q47117336

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Prediction of plasma efavirenz ...... nation antiretroviral therapy.

@en

Prediction of plasma efavirenz ...... nation antiretroviral therapy.

@nl

type

Item

label

Prediction of plasma efavirenz ...... nation antiretroviral therapy.

@en

Prediction of plasma efavirenz ...... nation antiretroviral therapy.

@nl

prefLabel

Prediction of plasma efavirenz ...... nation antiretroviral therapy.

@en

Prediction of plasma efavirenz ...... nation antiretroviral therapy.

@nl

P1476

Prediction of plasma efavirenz ...... nation antiretroviral therapy.

@en

P2093

Chien-Ching Hung

http://www.w3.org/2001/XMLSchema#string

Chin-Fu Hsiao

http://www.w3.org/2001/XMLSchema#string

Shu-Wen Lin

http://www.w3.org/2001/XMLSchema#string

Sui-Yuan Chang

http://www.w3.org/2001/XMLSchema#string

Wen-Chun Liu

http://www.w3.org/2001/XMLSchema#string

Ya-Ting Lin

http://www.w3.org/2001/XMLSchema#string

Yi-Ching Su

http://www.w3.org/2001/XMLSchema#string

P2860

The weight of nations: an estimation of adult human biomass

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.

An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients

Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations.

P2888

s41598-017-16483-2

P304

16187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-16483-2

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29170492

http://www.w3.org/2001/XMLSchema#string

P932

5701031

http://www.w3.org/2001/XMLSchema#string